Show simple item record

dc.contributor.authorSanaz Savabkar
dc.contributor.authorVahid Chaleshi
dc.contributor.authorFaegheh Behboudi Farahbakhsh
dc.contributor.authorMahdi Montazer Haghighi
dc.contributor.authorNeda Zali
dc.contributor.authorEhsan Nazemalhosseini Mojarad
dc.contributor.authorMohsen Vahedi
dc.contributor.authorGholam Reza Javadi
dc.contributor.authorHamid Asadzade Aghdaei
dc.contributor.authorMohammad Reza Zali
dc.date.accessioned2017-09-18T10:26:15Z
dc.date.available2017-09-18T10:26:15Z
dc.date.issued2015-01-01
dc.identifier.urihttp://dsp.sbmu.ac.ir/xmlui/handle/123456789/64244
dc.description.abstract© Mattioli 1885. Background/Aims: Vascular endothelial growth factor (VEGF) is a signal protein and plays a major role in angiogenesis and metastasis of tumors. Some variation in the 3’ untranslated region (3’UTR) of VEGF gene could alter the expression of this gene. In this study we have evaluated the possible association between +936C/T (rs3025039) polymorphism located in 3’UTR of VEGF gene and the risk of colo rectal cancer (CRC) in an Iranian population. Methods: In the present case-control study, VEGF genotypes of +936C/T polymorphism were determined in 200 patients with CRC and 200 control individuals. DNA was extracted from blood specimens and genotypes were analyzed by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Results: A significant correlation was found between +936C/T variant in the VEGF gene and CRC risk. Frequency of the TT genotype was 16% in controls and 2% in the case study. There was a statistically significant difference in TT genotype frequency between CRC patients and controls (adjusted OR= 0.229, 95% CI= 0.058-0.899; P=0.035). Conclusions: These results suggest that the TT genotype may have a protective effect against CRC in an Iranian population.
dc.sourceEuropean Journal of Oncology
dc.subject3’UTR
dc.subjectAngiogenesis
dc.subjectColorectal cancer
dc.subjectGenotypes
dc.subjectSNP
dc.subjectVEGF
dc.titleVEGF gene +936C/T polymorphism decreases the risk of colorectal cancer
dc.journal.volume20
dc.journal.issue2
dc.journal.pages88-93
dc.contributor.authorid55822198500
dc.contributor.authorid55789745100
dc.contributor.authorid56705322400
dc.contributor.authorid26635739500
dc.contributor.authorid24723036900
dc.contributor.authorid25824395200
dc.contributor.authorid26636085000
dc.contributor.authorid25925037400
dc.contributor.authorid55089994200
dc.contributor.authorid6602567324
dc.contributor.citation55822198500|60018934|Sanaz Savabkar
dc.contributor.citation55789745100|60018934|Vahid Chaleshi
dc.contributor.citation56705322400|60018934|Faegheh Behboudi Farahbakhsh
dc.contributor.citation26635739500|60031777|Mahdi Montazer Haghighi
dc.contributor.citation24723036900|60018934|Neda Zali
dc.contributor.citation25824395200|60018934|Ehsan Nazemalhosseini Mojarad
dc.contributor.citation26636085000|60027708|Mohsen Vahedi
dc.contributor.citation25925037400|60031777|Gholam Reza Javadi
dc.contributor.citation55089994200|60018934|Hamid Asadzade Aghdaei
dc.contributor.citation6602567324|60018934|Mohammad Reza Zali
dc.contributor.affiliationid60018934
dc.contributor.affiliationid60018934
dc.contributor.affiliationid60018934
dc.contributor.affiliationid60031777
dc.contributor.affiliationid60018934
dc.contributor.affiliationid60018934
dc.contributor.affiliationid60027708
dc.contributor.affiliationid60031777
dc.contributor.affiliationid60018934
dc.contributor.affiliationid60018934


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record